Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

Kudelka, Andrzej P.; Tresukosol, Damrong; Edwards, Creighton L.; Freedman, Ralph S.; Levenback, Charles; Chantarawiroj, Picharn; Leon, Cesar Gonzalez De; Kim, E. E.; Madden, Timothy; Wallin, Bruce A.; Hord, M.; Verschraegen, Claire F.; Raber, Martin N.; Kavanagh, John J.

doi:10.1200/jco.1996.14.5.1552

Cited by 229 publications

(115 citation statements)

References 9 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…No correlation between glomerular filtration rate or bilirubin level and hematological toxicity or response was reported. 18 Similarities were observed in this study (Table 4).…”

Section: Topotecansupporting

confidence: 88%

See 1 more Smart Citation

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

et al. 2000

View full text Add to dashboard Cite

“…No correlation between glomerular filtration rate or bilirubin level and hematological toxicity or response was reported. 18 Similarities were observed in this study (Table 4).…”

Section: Topotecansupporting

confidence: 88%

“…17,27,29 The median durations for grades 3 and 4 neutropenia and thrombocytopenia were 10 and 5 days, respectively. 18 Maculopapular pruritic exanthema occurred in 20% of patients. Gastrointestinal side effects were mild.…”

Section: Topotecanmentioning

confidence: 99%

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

et al. 2000

View full text Add to dashboard Cite

“…Three noncomparative phase II studies were conducted in patients with epithelial ovarian cancer (studies 012 [12], 033 [1], and 034 [4]) and three were conducted in patients with SCLC (studies 014 [6], 053 [14], and 092 [5]). A randomized, controlled, phase III study (study 039) [9,13] …”

Section: Pooled Studiesmentioning

confidence: 99%

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis

et al. 2005

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Explain the approved indications and treatment schedules for topotecan.2. Describe the typical pattern of hematologic toxicity during treatment with topotecan.3. Identify patients who are at higher risk for severe hematologic toxicity during treatment with topotecan. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

“…Data from phase II trials showed that topotecan has efficacy in both platinum-sensitive and platinum-resistant ovarian cancer [5][6][7][8][9][10][11]. Based on these studies, a 30-minute i.v.…”

Section: Introductionmentioning

confidence: 99%

Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer

Morris

2002

The Oncologist

View full text Add to dashboard Cite

Topotecan has demonstrated efficacy in the treatment of both platinum-sensitive and platinum-resistant recurrent ovarian cancer. However, the optimal dosing for topotecan has not been established. The standard dosing regimen is 1.5 mg/m 2 /day on days 1-5 of a 21-day cycle, with response rates ranging from 13%-33%. Although the resulting hematologic toxicities are reversible and noncumulative, this schedule is associated with significant myelosuppression. Ongoing clinical phase I and II trials have evaluated alternative dosing schedules such as the 21-day 24-hour continuous intravenous (c.i.v.), the 3-day i.v. bolus, the weekly 72-hour c.i.v., the weekly 24-hour c.i.v., and the weekly bolus i.v. regimens. Prolonged exposure to topotecan has been shown to increase the efficacy of topotecan, whereas shorter regimens decrease exposure to the drug and therefore decrease toxicity. Preliminary studies investigating the weekly bolus i.v. regimen have demonstrated response rates comparable with those achieved with the standard dosing regimen, with a lower frequency of severe toxicity. Although randomized, controlled comparative trials are necessary to determine relative efficacy, results from studies utilizing other alternative regimens are less encouraging, especially for lower-risk patients with platinum-sensitive ovarian cancer who are likely to tolerate higher doses of topotecan. Optimizing the dosing regimen will also increase the quality of life for the patient through increased efficacy, decreased toxicity, and increased convenience of administration. Continued investigation of the weekly i.v. bolus is needed to fully elucidate the contribution of this regimen to the current armamentarium used in the treatment of patients with relapsed ovarian cancer. The Oncologist 2002;7(suppl 5):29-35

show abstract

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

Cited by 229 publications

References 9 publications

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer

Hematologic Safety and Tolerability of Topotecan in Recurrent Ovarian Cancer and Small Cell Lung Cancer: An Integrated Analysis

Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer

Contact Info

Product

Resources

About